跳到正文
原文
Neurocrine Biosciences· @neurocrine · X·· 28 天前AI 评分42
AI 导读

今日我们宣布启动在研化合物NBI-‘567的II期临床研究,作为轻至中度阿尔茨海默病成人患者认知障碍的辅助治疗。NBI-‘567是一种选择性毒蕈碱激动剂,旨在激活参与学习、记忆及其他认知功能的M1和M4受体。 阅读新闻稿:https://neurocrine.gcs-web.com/news-releases/news-release-details/neurocrine-biosciences-initiates-phase-2-clinical-study-1

正文

Today we announced the initiation of a Phase 2 clinical study of investigational compound NBI-‘567 as an adjunctive treatment for cognitive impairment in adults with mild to moderate Alzheimer’s disease. NBI-‘567 is a selective muscarinic agonist designed to activate M1 and M4 receptors involved in learning, memory and other cognitive functions.

Read the release: https://neurocrine.gcs-web.com/news-releases/news-release-details/neurocrine-biosciences-initiates-phase-2-clinical-study-1

来源:Neurocrine Biosciences · x.com